M. Stranieri

发表

Species Variability in Platelet and other Cellular Responsiveness to Thrombin Receptor-derived Peptides

R. Nutt, R. Gould, R. Gould, 1994, Thrombosis and Haemostasis.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.

J. Lynch, J. Cook, I. I. Stabilito, 1995, The Journal of pharmacology and experimental therapeutics.

Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.

J. Lynch, I. I. Stabilito, M. Holahan, 1993, The Journal of pharmacology and experimental therapeutics.

Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis

J. Lynch, I. I. Stabilito, G. Vlasuk, 1993 .

Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.

R. Gould, G. Hartman, J. Hutchinson, 1996, Journal of medicinal chemistry.

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.

J. Baldwin, T. Prueksaritanont, R. Gould, 1997, Journal of medicinal chemistry.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.

J. Baldwin, R. Gould, G. Hartman, 1997, The Journal of pharmacology and experimental therapeutics.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist

P. Anderson, J. Baldwin, R. Gould, 1997 .

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Daniel R McMasters, James C Barrow, W. M. Sanders, 2003, Journal of medicinal chemistry.

Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.

J. Vacca, J. Shafer, Z. Chen, 1998, Journal of medicinal chemistry.

C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption.

J. Vacca, S. Gardell, S. D. Lewis, 1998, Bioorganic & medicinal chemistry letters.

L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.

J. Vacca, J. Shafer, Z. Chen, 1998, Bioorganic & medicinal chemistry letters.

Pharmacokinetics and Pharmacodynamics of L-703,014, a Potent Fibrinogen Receptor Antagonist, After Intravenous and Oral Administration in the Dog

J. Barrett, R. Gould, G. Hartman, 1994, Pharmaceutical Research.

Nonpeptide GPIIb/IIIa inhibitors. 10. Centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregation

R. Gould, G. Hartman, S. Gaul, 1996 .

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.

Youwei Yan, L. Kuo, J. Vacca, 2003, Bioorganic & medicinal chemistry letters.

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.

S. Brady, J. Vacca, S. Gardell, 1998, Journal of medicinal chemistry.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.

R. Gould, G. Hartman, N. Ihle, 1996, The Journal of pharmacology and experimental therapeutics.

Effects of the novel calcium channel blocker, McN-5691, on cardiocirculatory dynamics and cardiac output distribution in conscious spontaneously hypertensive rat.

A. Gill, J. Carson, S. Flaim, 1988, Journal of Cardiovascular Pharmacology.

Simple high-performance liquid chromatographic method to analyze serum creatinine has several advantages over the Jaffé picric acid reaction as demonstrated with a cimetidine dose response in rhesus monkeys.

T. Broten, J. Cook, M. Holahan, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.

R. Gould, G. Hartman, S. Gaul, 1999, Journal of medicinal chemistry.

Effects of the Novel Coronary Selective Calcium Channel Blocker, McN‐6186, on Cardiocirculatory Dynamics Coronary Vascular Resistance, and Cardiac Output Distribution in Normal, Conscious Rats

A. Gill, J. Carson, S. Flaim, 1990, Journal of cardiovascular pharmacology.

Investigation of (Oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines.

D. Bindra, G. Rork, J. Cook, 1996, Journal of medicinal chemistry.

Nonpeptide glycoprotein IIB/IIIA inhibitors. 12. Potent and orally active centrally constrained thieno[2,3-c]pyridones

R. Gould, G. Hartman, J. Lynch, 1996 .

Nonpeptide GPIIB/IIIA inhibitors. 16. Thieno[2,3-b]thiophene α-sulfonamides are potent inhibitors of platelet aggregation

G. Hartman, J. D. Prugh, R. Bednar, 1997 .

Effect of E‐4031, a Class III Antiarrhythmic Agent, on Experimental Infarct Size in a Canine Model of Myocardial Ischemia‐Reperfusion Injury

J. Lynch, M. Holahan, I. Stabilito, 1992, Journal of cardiovascular pharmacology.